(NASDAQ: ABOS) Acumen Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 4.79%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.38%.
Acumen Pharmaceuticals's earnings in 2025 is -$136,665,000.On average, 3 Wall Street analysts forecast ABOS's earnings for 2025 to be -$135,484,580, with the lowest ABOS earnings forecast at -$142,347,549, and the highest ABOS earnings forecast at -$125,386,990.
In 2026, ABOS is forecast to generate -$95,706,012 in earnings, with the lowest earnings forecast at -$101,157,620 and the highest earnings forecast at -$87,831,466.